Selected articles
Articles for label Zvaríková Mária are displayed.. Show all articles
Targeted therapy for ovarian cancer – case report
05/2018 MUDr. Mária Zvariková
Treatment of epithelial ovarian cancer is historically based on surgery and platinum doublet chemotherapy and is associated with high risk of relapse and poor prognosis in recurrent disease. Innovative treatment with PARP inhibitors has demonstrated an outstanding activity in epithelial ovarian cancer and is currently changing clinical practice in patients with BRCA mutation in genes.
ENTIRE ARTICLE
Treatment of epithelial ovarian cancer is historically based on surgery and platinum doublet chemotherapy and is associated with high risk of relapse and poor prognosis in recurrent disease. Innovative treatment with PARP inhibitors has demonstrated an outstanding activity in epithelial ovarian cancer and is currently changing clinical practice in patients with BRCA mutation in genes.
Treatment of patients with ovarian carcinoma with a BRCA1/2 mutation present
01/2018 MUDr. Mária Zvaríková
Poly(ADP-ribose)polymerase inhibitors (PARP) are considered to be one of the most exciting new options for patients with ovarian carcinoma. In monotherapy, PARP inhibitors have shown the greatest activity in tumor cells carrying mutations in BRCA genes. Recent Phase III studies have shown that PARP inhibitor activity is also present in nonmutated patients, especially if they have certain clinical characteristics such as platinum sensitivity and histologically verified high-grade serous carcinoma. PARP inhibitors were also combined with chemotherapy, but overlapping myelosuppression was observed with both PARP inhibitors and chemotherapy, inhibiting the development of these combinations. In contrast, combinations of PARP inhibitors and biological agents, particularly antiangiogenic agents, appear to be well tolerated and show promising activity in both BRCA mutants and wild type BRCA. There are currently numerous clinical trials investigating the anti-tumor activity of combination therapy of PARP inhibitors.
ENTIRE ARTICLE
Poly(ADP-ribose)polymerase inhibitors (PARP) are considered to be one of the most exciting new options for patients with ovarian carcinoma. In monotherapy, PARP inhibitors have shown the greatest activity in tumor cells carrying mutations in BRCA genes. Recent Phase III studies have shown that PARP inhibitor activity is also present in nonmutated patients, especially if they have certain clinical characteristics such as platinum sensitivity and histologically verified high-grade serous carcinoma. PARP inhibitors were also combined with chemotherapy, but overlapping myelosuppression was observed with both PARP inhibitors and chemotherapy, inhibiting the development of these combinations. In contrast, combinations of PARP inhibitors and biological agents, particularly antiangiogenic agents, appear to be well tolerated and show promising activity in both BRCA mutants and wild type BRCA. There are currently numerous clinical trials investigating the anti-tumor activity of combination therapy of PARP inhibitors.